19 March 2024
19 March 2024
Treatment with the Imfinzi and Lynparza regimen caused a 32% reduction in the second progression or mortality risk.
Medidata is hoping that the trial will help to establish the cardiac effort digital biomarker and establish new digital biomarkers.
The trial will evaluate the safety, tolerability, efficacy, pharmacokinetics and electrophysiology of ANAVEX3-71.
According to the trial findings, both IBI302 groups demonstrated non-inferiority to the Aflibercept arm.
This year’s CTS Europe 2024 conference discussed topics such as sustainability, sector challenges and trends, and artificial intelligence (AI).
Sustained transmission of TB may be due to the presence of undiagnosed and drug-treated cases alongside active infections.
Intellia Therapeutic’s NTLA-2001 is the first in vivo CRISPR-Cas 9 candidate to make late-stage trials.
The trial met its primary efficacy endpoint of the percentage change from baseline in liver fat content.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
